(NASDAQ: EYPT) Eyepoint Pharmaceuticals's forecast annual revenue growth rate of 22.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Eyepoint Pharmaceuticals's revenue in 2025 is $56,042,000.On average, 4 Wall Street analysts forecast EYPT's revenue for 2025 to be $2,764,305,059, with the lowest EYPT revenue forecast at $1,912,966,261, and the highest EYPT revenue forecast at $4,335,139,368. On average, 4 Wall Street analysts forecast EYPT's revenue for 2026 to be $1,054,883,913, with the lowest EYPT revenue forecast at $178,910,514, and the highest EYPT revenue forecast at $3,492,883,719.
In 2027, EYPT is forecast to generate $10,090,552,967 in revenue, with the lowest revenue forecast at $3,708,952,570 and the highest revenue forecast at $16,472,153,364.